EMPagliflozin outcomE tRial in Patients With chrOnic heaRt Failure With Preserved Ejection Fraction (EMPEROR-Preserved)

    Not Recruiting
  • participants needed
  • sponsor
    Boehringer Ingelheim
Updated on 20 June 2021
Boehringer Ingelheim Call Center
Primary Contact
Cardiac Health Management Network, P.C. (4.2 mi away) Contact
+807 other location
medical therapy
ejection fraction
heart disease
chronic heart failure
b-type natriuretic peptide
natriuretic peptide
heart failure with preserved ejection fraction


The aim of the study is to evaluate efficacy and safety of empagliflozin versus placebo on top of guideline-directed medical therapy in patients with heart failure with preserved ejection fraction

Condition Heart failure, Heart disease, Congestive Heart Failure, Cardiac Disease
Treatment Placebo, Empagliflozin
Clinical Study IdentifierNCT03057951
SponsorBoehringer Ingelheim
Last Modified on20 June 2021

Similar trials to consider


Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note